Related Experiment Video
Updated: Jun 23, 2026
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments
Amir M Ansari1, Sogol Attaripour1, Sahil Garg1
1Department of Medicine, Division of Hematology and oncology, Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, USA.
Abstract:
The treatment landscape for multiple myeloma (MM) has evolved significantly over the years; however, the disease remains incurable. Heavily pretreated patients with refractory disease to anti-CD38 therapies, proteasome inhibitors (PIs), and immunomodulatory drugs (IMiDs) face a very poor prognosis. Bispecific antibodies (BsAbs) are the newest, and most promising available therapy for heavily pretreated patients with relapsed refractory multiple myeloma (RRMM). BsAbs primarily rely on T cell activation to target cancer cells by binding malignant plasma cells to cytotoxic T cells via surface antigens. BsAbs consist of two binding sites: one that targets a specific antigen on the surface of MM cells, such as B-cell maturation antigen (BCMA), G-protein-coupled receptor class C group 5 member D (GPRC5D), or fragment crystallizable receptor-like 5 (FcRH5), and another that binds to CD3, a T-cell receptor. Ongoing research aimed at optimizing sequencing strategies, mitigating toxicity, and evaluating combination approaches will be critical to maximizing the durability of response and improving long-term outcomes in this high-risk population.
Insights
Bispecific antibodies (BsAbs) offer a promising new therapy for relapsed refractory multiple myeloma (RRMM) patients who have exhausted other treatments. Further research will optimize BsAbs for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Multiple myeloma (MM) remains incurable despite treatment advances.
- Patients with refractory disease to anti-CD38 therapies, proteasome inhibitors (PIs), and immunomodulatory drugs (IMiDs) have a poor prognosis.
- Relapsed refractory multiple myeloma (RRMM) presents significant therapeutic challenges.
Purpose of the Study:
- To highlight bispecific antibodies (BsAbs) as a novel and promising therapeutic option for heavily pretreated RRMM patients.
- To explain the mechanism of action of BsAbs in targeting multiple myeloma cells.
- To emphasize the importance of ongoing research in optimizing BsAb therapy.
Main Methods:
- Review of current treatment landscape for multiple myeloma.
- Description of the mechanism of action for bispecific antibodies (BsAbs).
- Identification of key antigens targeted by BsAbs, including BCMA, GPRC5D, and FcRH5.
Main Results:
- Bispecific antibodies (BsAbs) represent a new frontier in treating heavily pretreated RRMM.
- BsAbs function by bridging T cells and malignant plasma cells through specific antigen binding.
- The efficacy of BsAbs relies on T cell activation against cancer cells expressing target antigens.
Conclusions:
- Bispecific antibodies (BsAbs) are a vital advancement for patients with refractory multiple myeloma (MM).
- Optimizing sequencing, managing toxicity, and exploring combination therapies are crucial for maximizing BsAb effectiveness.
- Continued research is essential to improve long-term outcomes for high-risk RRMM patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...